In 2004, Klinger [16] showed that an antibody against Lewis y blocks the signal pathway mediated by EGFR and inhibits activation of RAS and phosphorylation of MAPK, in turn, suppressing carcinoma cell proliferation. Here, EGFR is linked to carcinoma.